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Background: Insulin resistance heightens the risk for type 2 diabetes mellitus and cardiovascular disease.
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improves insulin action in individuals with insulin-resistant diabetes and nondiabetic individuals.
However, there are few reports on the time of onset of such effects independent of reversal of glucotoxicity.
Objective: The goal of our study was to test whether the thiazolidinedione pioglitazone has prominent
early metabolic effects that can be detected in an obese, nondiabetic, insulin-resistant population.
Methods: We conducted a randomized, double-blind, placebo-controlled, parallel-group trial in men with
nondiabetic insulin resistance using a hyperinsulinemic euglycemic clamp technique (at low and high
doses of insulin at 10 and 40 mU/m2/min, respectively). The patients were given 30 mg daily oral
pioglitazone or placebo for 28 days. Patients underwent a baseline clamp before initiation of treatment,
and again at 14 and 28 days of treatment.
Results: Compared with placebo, under high-dose hyperinsulinemia, pioglitazone led to signiﬁcant
increases in glucose disposal rates (GDR) of 1.29 mg/kg/min (90% CI, 0.43–2.15; 39%; P¼0.008) that were
detectable at 2 weeks of treatment and persisted at 4 weeks of treatment. Under low-dose hyper-
insulinemia, signiﬁcant increases in GDR of 0.40 mg/kg/min (90% CI, 0.17–0.62; 95%; P¼0.003) were
observed at 4 weeks of treatment. These responses were accompanied by robust suppression of free fatty
acids under hyperinsulinemic conditions, and by signiﬁcant increases in circulating basal total adiponectin
at 2 and 4 weeks of treatment.
Conclusions: Signiﬁcant changes in insulin action across multiple insulin-sensitive tissues can be detected
within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with
nondiabetic insulin resistance. ClinicalTrials.gov identiﬁer: NCT01115712.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Insulin resistance (IR) is an integral aspect of the pathogenesis
of type 2 diabetes mellitus (T2DM) and is independently associ-
ated with cardiovascular (CV) risk.1 Amelioration of IR can be
beneﬁcial for both the prevention and treatment of T2DM.2,3 IR can
be partially normalized by exercise and weight loss, with addi-
tional contribution from pharmacologic therapy. Thiazolidine-
diones (TZDs) activate the transcription factor peroxisome
proliferator-activated receptor gamma (PPARγ),4 and TZDs, besides
metformin, are generally acknowledged as the only class of oral
antihyperglycemic agents with therapeutically relevant effects onInc. This is an open access article u
MD, (Current address) Lilly
Code 1940, Indianapolis, IN
. Shankar).peripheral glucose disposal.5 However, with the emergence of
signiﬁcant concerns about side effects, the use of TZDs has
declined6–8 and there is therefore an urgent need for newer
insulin-sensitizing therapies.
The development of novel insulin-sensitizing therapies requires
a clear understanding of the tissue site of insulin action of the
novel agent, as well as the time of onset of such effects. For
practical purposes, it is important to have a simple yet reliable
means to perform such interrogation of insulin action early in
development, and especially useful to be able to calibrate the novel
treatment with the standard of care, which at the time of writing is
a TZD. It is of particular interest to ascertain early responses to
TZDs in individuals with nondiabetic IR because the interpretation
of changes in IR would not be confounded by potential, and
possibly variable, alleviation of glucotoxicity.
Various methodologies have been developed for clinical assess-
ment of IR, including the frequently sampled intravenous glucosender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tolerance test (OGTT) or meal tolerance test (MTT).10 However, the
gold standard methodology remains the euglycemic clamp under
exogenous insulinization.11 A number of clinical investigations
have used the euglycemic clamp to examine the improvement in
IR in response to TZD agents.12–14 These studies have yielded
considerable insights into the mechanisms by which PPARγ acti-
vation alters IR and glucose homeostasis, but nearly all were
conducted after a treatment period of several months, when the
response has presumably fully equilibrated.3,15–17 Few studies have
sought to examine leading-edge changes in IR early in the course
of treatment with TZD,18,19 and none have assessed early changes
in obese human beings with nondiabetic IR in a controlled setting.
The goal of the present study was to appraise the onset of
clinically relevant changes in IR in response to treatment with the
TZD agent pioglitazone (PIO) using a 2-step euglycemic hyper-
insulinemic clamp at 2 and 4 weeks of treatment in obese men
with nondiabetic IR, with potential application of these ﬁndings as
a benchmark for the evaluation of novel insulin-sensitizing thera-
pies. Prior studies suggest that measurable changes can occur
within an interval of 12 weeks20–23; however, none of these
reported data earlier in the course of treatment. Two trials of
antihyperglycemic therapy in T2DM18,19 and a single uncontrolled
trial in a small group of nonobese patients without diabetes
suggested improvements as early as 3 weeks of treatment.24 Our
ﬁndings demonstrate for the ﬁrst time in obese volunteers with
nondiabetic IR in a randomized, double-blind, placebo-controlled
setting, that improvement of IR can be clearly detected within
2 weeks of initiation of treatment with PIO. Furthermore, we
demonstrate that this improvement is measurable across multiple
key tissues involved in the pathogenesis of IR, including adipose,
hepatic, and skeletal muscle tissues, suggesting that interorgan
crosstalk likely originating from adipose tissue is already evident
and is measurable systemically very early in the course of
treatment.Methods
Study Participants
All patients were overweight or obese (body mass index
428 kg/m2 and r38 kg/m2) men without diabetes by clinical
history and fasting glucose measurement and normotensive by cuff
measurements per the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
(JNC VI).25 Participants also had normal cholesterol levels per the
Third Report of the National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (NCEP III) criteria,26 and were not taking any
medications routinely. All patients provided informed consent for
the trial.
Study Drugs
The 30 mg PIO (Takeda Pharmaceuticals USA Inc., Deerﬁeld,
Illinois) or placebo was administered as a daily oral dose for 28
consecutive days.
Protocol
This was a randomized, double-blind, placebo-controlled study
with a parallel-group design for treatment groups. The study
(Protocol 170) was conducted between 2009 and 2010 at a Phase
I clinical research unit (ICON Development Solutions, San Antonio,
Texas) with approval from the local ethics review committee(IntegReview Ethical Review Board, San Antonio, TX). The trial
was conducted in accordance with principles of Good Clinical
Practice. Patients meeting study entry criteria underwent a hyper-
insulinemic euglycemic clamp at baseline and were randomly
allocated to 1 of 2 treatments (30 mg PIO or placebo). Patients
underwent a second hyperinsulinemic euglycemic clamp after 14
days of treatment and a third hyperinsulinemic euglycemic clamp
after 28 days of treatment. A total of 38 patients completed the
baseline clamp procedure, and 31 and 29 patients completed the
Day 14 and Day 28 clamp procedures, respectively.
The euglycemic clamp was performed in 2 steps each lasting
approximately 180 minutes: a low-dose portion with insulin
infusion rates of 10 mU/m2/min followed by a high-dose portion
with infusion rates of 40 mU/m2/min. The clamp procedures were
performed using the method described by DeFronzo et al27 with
target plasma glucose levels of approximately 90 mg/dL. Samples
for measurement of insulin and free fatty acids (FFA) were
obtained at baseline and at steady state of each step of the clamp.
The key end points of the trial were the effects of PIO compared
with placebo on insulin sensitivity, measured as average changes in
glucose disposal rates (GDR) from baseline at 28 days and 14 days
corrected for body weight (M) at steady state of the clamp during
the high- and low-dose portions. Additional end points included
M/SSPG (M normalized to plasma glucose at steady state); M/I
(M normalized to plasma insulin at steady state); circulating levels
of fasting insulin, FFA, adiponectin, and retinol binding protein 4
(RBP4); and insulin-induced suppression of FFA. All measurements
were performed using commercially available assays.
Statistical Methods
For comparison of the treatment groups with respect to the
change from baseline for each end point, a constrained longitudi-
nal data analysis method was used. This model assumes a common
mean across treatment groups at baseline and a different mean for
each treatment at each of the postbaseline time points. In this
model, the response vector consists of baseline and the values
observed at each postbaseline time point; that is, M at baseline, 14
days, and 28 days for the low- and high-dose portions of the
clamp. Time is treated as a categorical variable so that no
restriction is imposed on the trajectory of the means over time.
The analysis model was adjusted for baseline glucose level and
baseline insulin level. An unstructured covariance matrix was used
to model the correlation among repeated measurements. A closed-
testing procedure was employed to test the 2 primary hypotheses
whereby the difference between 30 mg PIO and placebo with
respect to the change in M from baseline at 28 days was tested
ﬁrst, and only if this hypothesis was met was the hypothesis at 14
days tested. This ensured that the overall type I error rate was
controlled at the 0.05 1-sided level. One-sided conﬁdence testing
was used because the direction of the PIO effect on M is known.28
Further analysis was conducted to assess the reproducibility of
M, insulin, and M normalized to plasma insulin at steady state
(M/I) for the low- and high-dose insulin infusion clamps. Data
from patients in the placebo group were used in this analysis and
reproducibility was assessed over 3 time points: baseline (Day 0),
Day 14, and Day 28. The concordance correlation coefﬁcient (CCC)
was computed to assess reproducibility.Results
Overweight and obese patients with nondiabetic IR were
randomly assigned in a double-blind manner to PIO and placebo
(PLB) treatment groups. As shown in Table I, the 2 groups were
well matched for demographic and metabolic variables, including
Table I
Baseline demographic and metabolic characteristics of the study groups.
Characteristic 30 mg Pioglitazone (n ¼ 19) Placebo (n ¼ 17) P value (2-sided)*
Mean SEM Mean SEM
Age, y 28.6 1.9 30.5 1.6 0.454
Body mass index 32.5 0.6 32.3 0.7 0.646
Systolic blood pressure, mm Hg 120.5 2.5 120.8 2.2 0.932
Diastolic blood pressure, mm Hg 79.3 1.9 77.8 1.6 0.556
Total cholesterol, mg/dL 181.1 8.1 195.2 9.5 0.265
Triglyceride, mg/dL 183.0 20.1 171.4 10.7 0.624
n P value is from a 2-sample t test.
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clamp and the groups were well matched (P40.05) for M at
baseline, as shown in Table II. During all the clamp studies, plasma
glucose was maintained at a target level of 90 mg/dL. Steady state
plasma insulin levels during each of the 2 steps of the clamp
studies were matched across groups at baseline, 2 weeks of
treatment, and 4 weeks of treatment. Clamp data are shown in
Figures 1 and 2 and presented in Table II.
During PIO treatment, M increased signiﬁcantly from baseline
and in comparison to PLB treatment, with these increases becom-
ing evident at 2 weeks of treatment. At 2 weeks of PIO treatment,
M increased by 40% (P ¼ 0.045) during the 40 mU/m2/min step of
the insulin infusion. Although glucose disposal also improved over
2 weeks during the 10 mU/m2/min infusion, the change in M was
not statistically signiﬁcant. Suppression of plasma FFA in response
to insulin infusion was greater with PIO treatment than with
placebo at 2 weeks during infusion with 10 and 40 mU/m2/min
insulin (P o 0.05). At 4 weeks of treatment, the improvement in M
during PIO treatment was evident and signiﬁcant during both the
10 mU/m2/min infusion step (95% increase; P¼0.003) and the 40
mU/m2/min infusion step (39% increase; P ¼ 0.008). At 4 weeks of
treatment, the greater suppression of plasma FFA with PIO com-
pared with placebo was evident only during the 10 mU/m2/minTable II
Glucose, insulin, glucose disposal rate (GDR), and free fatty acid (FFA) levels at Day 0, 14
hyperinsulinemic euglycemic clamp.
Variable Day 30 mg
Mean
Steady state glucose (mg/dL): Low dose 0 90.5
14 89.6
28 89.9
Steady state glucose (mg/dL): High dose 0 89.2
14 90.3
28 89.2
Steady state insulin (mcIU/mL): Low dose 0 34.5
14 31.7
28 29.9
Steady state insulin (mcIU/mL): High dose 0 106.1
14 104.2
28 104.1
GDR (mg/kg/min): Low dose 0 0.74
14 0.94
28 1.12
GDR (mg/kg/min): High dose 0 4.85
14 5.8
28 6.27
FFA (mmol/L): Low dose 0 0.182
14 0.123
28 0.102
FFA (mmol/L): High dose 0 0.048
14 0.038
28 0.035
n P value is a 1-sided P value from a constrained longitudinal data analysis model forinsulin infusion. Supplementary analyses of M normalized to
plasma insulin at steady state (M/I) and M normalized to plasma
glucose at steady state (M/SSPG) yielded similar results (data not
shown).
In response to PIO, circulating adiponectin increased by 50%
at Week 2 and by 80% at Week 4 (P o 0.01 compared with
placebo) (Table III). There was not a signiﬁcant correlation
between changes in adiponectin and changes in M. Whereas the
clamp data provided clear support for the notion that the effects of
PIO on insulin sensitivity can be measured as early as 2 weeks after
treatment initiation, most of the fasting parameters measured
revealed little change (Table III). Fasting glucose did not change
from baseline in either group across the study period, whereas
fasting levels of insulin decreased slightly (25%) in the PIO group,
although this difference was signiﬁcant only at 2 weeks of treat-
ment. Fasting levels of plasma FFA and retinol binding protein
4 were not different between the groups at baseline, 2 weeks of
treatment, or 4 weeks of treatment.
An ancillary goal was to assess the reproducibility of M in the
PLB-treated group across a relatively brief interval of 4 weeks of
treatment. Taking into consideration the baseline, 2-week, and
4-week clamp determinations in the PLB group, there was an
observed CCC of 0.70 and 0.73 for M values obtained during the, and 28 during steady-state conditions for the low- and high-dose conditions of a
Pioglitazone Placebo P value*
SEM Mean SEM
0.4 89.8 0.2 –
0.1 89.9 0.3 –
0.2 89.7 0.2 –
0.4 89.9 0.6 –
0.9 90.0 0.4 –
0.7 89.9 0.6 –
1.3 32.0 1.8
1.6 33.4 2.8 –
1.7 32.1 2.0 –
3.4 105.5 3.9 –
4.2 109.6 5.7 –
4.2 105.5 4.4 –
0.11 0.93 0.21 –
0.11 0.83 0.15 0.069
0.16 0.64 0.11 0.003
0.46 6.16 0.57 –
0.63 5.86 0.60 0.045
0.53 5.52 0.50 0.008
0.015 0.180 0.030
0.012 0.147 0.016 0.028
0.013 0.159 0.017 0.009
0.003 0.046 0.008
0.004 0.042 0.006 0.031
0.004 0.047 0.007 0.064
comparing the change from baseline for the given end point between the 2 groups.
***
**
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Figure 2. Means and SE for change (Δ) from baseline in glucose disposal rate per kg
body weight (mg/kg/min) (M) across the entire duration of the clamp performed at
Day 28 of treatment with 30 mg pioglitazone or placebo. Insulin was admin-
istered at a low dose (10 mU/m2/min) from 0 to 180 minutes, and at a high dose
(40 mU/m2/min) from 180 to 360 minutes.
Table III
Body weight, fasting glucose, fasting insulin, fasting free fatty acid (FFA), receptor
binding protein 4 (RBP4), and adiponectin at Day 0, 14, and 28.
Variable Day 30 mg Pioglitazone Placebo P value*
Mean SEM Mean SEM
Body weight, kg 0 100.9 2.8 96.9 3.4 –
14 99.1 3.0 96.9 3.7 0.173
28 100.6 3.0 97.7 4.1 0.231
Fasting glucose, mg/dL 0 97.6 1.7 99.0 1.5 –
14 96.6 1.1 98.1 1.5 0.303
28 96.3 1.4 98.6 1.7 0.408
Fasting insulin, mcIU/mL 0 18.4 1.8 15.2 1.9 –
14 14.2 1.6 14.9 1.8 0.005
28 13.9 1.7 15.0 1.7 0.074
Fasting FFA, mmol/L 0 0.48 0.018 0.50 0.031 –
14 0.42 0.033 0.46 0.039 0.272
28 0.45 0.031 0.49 0.032 0.307
RBP4, mg/mL 0 9.62 0.922 8.48 0.691 –
14 9.95 0.983 8.30 0.960 0.227
28 11.15 1.266 9.68 0.743 0.491
Adiponectin, mg/mL 0 10.27 0.816 11.22 1.539 –
14 15.90 2.097 9.67 0.690 0.003
28 18.38 2.840 10.91 0.913 0.007
n P value is a 1-sided P value from a constrained longitudinal data analysis
model for comparing the change from baseline for the given end point between the
2 groups.
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Figure 1. Means and SE for change (Δ) from baseline in glucose disposal rate per
kilogram body weight (mg/kg/min) (M) across the entire duration of the clamp
performed at Day 14 of treatment with 30 mg pioglitazone or placebo. Insulin was
administered at a low dose (10 mU/m2/min) from 0 to 180 minutes, and at a high
dose (40 mU/m2/min) from 180 to 360 minutes.
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(Figure 3A). The insulin levels during the low-dose and the
high-dose insulin infusion in the PLB-treated group were compa-
rable on all 3 occasions (Figure 3B).120
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Figure 3. (A) Mean glucose disposal rate (GDR) (mg/kg/min) in the placebo group.
(B) Mean insulin concentration (mcIU/mL) in the placebo group.Discussion
The goal of our trial was to determine the onset of clinically
relevant changes in insulin action in various insulin-sensitive
tissues in response to 2- and 4-week treatment with PIO in the
setting of a placebo-controlled trial in obese volunteers with
nondiabetic IR. The key ﬁnding of this trial was the observation
of a substantial improvement in glucose disposal under hyper-
insulinemia in obese individuals with nondiabetic IR who were
otherwise healthy as early as after 2 weeks of PIO treatment. This
was accompanied by a concomitant signiﬁcant improvement in
suppression of FFA under hyperinsulinemia and a signiﬁcant
increase in basal adiponectin levels. These effects persisted at
4 weeks of treatment, with evidence of suppression of endogenous
glucose production and no change in basal fasting glucose, FFA, or
other lipid parameters.
Although diet and exercise remain the foundation of treatment
of T2DM, especially for alleviation of IR, the development of novel
pharmacologic treatments that alleviate IR could be of substantial
S.S. Shankar et al. / Current Therapeutic Research 77 (2015) 83–89 87value in addressing the growing epidemic of T2DM. Identifying
new targets for amelioration of IR and choosing those most likely
to translate preclinical efﬁcacy in rodents into efﬁcacy in human
beings is recognized to be highly challenging because the patho-
genesis of IR remains controversial and is probably multifacto-
rial.29,30 Perhaps as a consequence of this complexity of IR and
uncertainty over the molecular causes of IR, the clinical translation
of novel targets that are typically identiﬁed in rodent models of
diabetes and obesity seems fraught by failures. There is no facile
solution for this challenge, but our study addresses 1 aspect that
we posit to be crucial, namely provision of a relevant rationale and
a simple yet reliable paradigm to efﬁciently and rapidly test the
therapeutic effects of a novel insulin-sensitizing mechanism. We
used a 2-step hyperinsulinemic euglycemic clamp, a well-
described methodology, to assess early changes in IR evoked by
PIO, a TZD, and the standard of care for pharmacologic treatment
of IR. Two dose levels of insulin infusion, low and high, were used
as windows of sensitivity to assess changes in adipose tissue and
liver at the low dose, and to more clearly probe changes in glucose
disposal within peripheral tissues, notably skeletal muscle, at the
high dose. Signiﬁcant improvements in IR were observed in
response to PIO therapy, with changes evident at 2 weeks of
treatment and persisting, possibly even further improving, over
4 weeks of treatment. From a practical perspective, as well as from
intent to achieve some clarity in assessing pharmacodynamic
response in a relatively small number of patients, this 2- to
4-week window is quite efﬁcient and useful. Although it is
possible that not all novel mechanisms for treating IR will
demonstrate a similar early pattern of changes that we observed
for a TZD, presumably the temporal pattern of improvement seen
with novel mechanisms for IR in preclinical studies will shed light
on a potential time course that can be anticipated for clinical
improvement and, therefore, whether assessment and comparison
to a TZD benchmark at 2 weeks of treatment seems rational. In
addition, knowing the magnitude of improvement in insulin action
at each of the key tissues may provide insight into the integrated
therapeutic effect that might be anticipated from a novel insulin
sensitizer.
The improvement in IR observed in our study at 2 weeks and
4 weeks of treatment with PIO complements the ﬁndings of
several clinical studies on changes in IR following several months
of TZD treatment in populations with T2DM. Interestingly, in this
group of overweight and obese men with nondiabetic IR, an
approximately 40% improvement in IR was observed during the
high-dose insulin infusion (40 mU/m2/min) at 2 weeks; this was
sustained at 4 weeks of treatment and was similar to the improve-
ment in IR observed after several months of TZD treatment in
other studies.15,23,31 This similarity, in response, supports the
rationale and robustness of the paradigm and methods employed
in the current trial, namely the use of a simple 2-step hyper-
insulinemic euglycemic clamp in patients with nondiabetic IR
performed early in the course of treatment. The mechanism by
which TZDs improve IR through activation of PPARγ receptors,
mainly in adipocytes and preadipocytes,12,19 remains incompletely
understood. At 2 weeks of PIO treatment, in addition to the
improvement in glucose disposal, there was a notable improve-
ment in insulin-mediated suppression of plasma FFA and an
increase in plasma adiponectin levels. Adiponectin is a biomarker
of TZD action in adipose tissue32,33 and, together with the
increased suppression of plasma FFA, signiﬁes changes in adipose
tissue IR; the concordance in these changes makes our ﬁndings
particularly robust.
These changes in adipose tissue metabolism, together with the
increase in glucose disposal observed during the high-dose insulin
infusion, suggest crosstalk between adipose tissue and skeletal
muscle in mediating the early improvement in IR. In contrast,although FFA levels were nearly completely suppressed during the
low-dose insulin infusion at 2 weeks, the corresponding M val-
ues during this step of the clamp were unchanged from basal
and across groups. However, by 4 weeks of PIO treatment, M
values during the low-dose insulin infusion had nearly doubled
(P o 0.01), indicating progressive improvement in an aspect of IR
that was not evident at 2 weeks of treatment. Our interpretation is
that this improvement from 2 to 4 weeks of PIO treatment that
becomes manifest during the low-dose insulin infusion represents
progressive improvement in hepatic IR. Although a more precise
delineation of the respective contributions of improvements of IR
in the liver and the periphery could perhaps have been attained
using glucose isotope tracer methodology during the clamp
studies, our ﬁndings are consistent with those reported in T2DM
after 3 weeks of PIO treatment.19 It should be noted that the low-
dose insulin infusion of 10 mU/m2/min, which was chosen to
assess changes in suppression of endogenous glucose production,
provided circulating levels of insulin sufﬁcient to suppress FFA and
at least partially suppress endogenous glucose production while
remaining lower than the exposures required to robustly stimulate
peripheral glucose disposal (42-fold augmentation over fasting
levels). In contrast, circulating insulin levels showed a 5-fold
augmentation over fasting levels during the high-dose insulin
infusion of 40 mU/m2/min, which was associated with a 40%
increase in M. Taken together, these ﬁndings suggest that the
doses of exogenous insulin selected and the levels of hyper-
insulinemic exposures achieved in this trial successfully provide
insight into the magnitude and temporal proﬁle of changes in
insulin action at adipose, hepatic, and skeletal muscle tissues in a
population with IR in a single experiment.
The fact that the improvement in M during the low-dose
insulin infusion was evident at 4 weeks of treatment but not at
2 weeks, whereas the suppression of FFA and increase in M during
the high-dose insulin infusion remained stable between 2 and
4 weeks of treatment, likely signiﬁes progressive improvement in
hepatic IR. We did not measure changes in body composition
during these brief studies and there was no weight loss among our
patients. But even in the context of TZD-induced weight gain, a
decrease in hepatic fat content during TZD treatment has been
observed.33,34 In a separate study, we observed a 20% decrease in
hepatic fat content in obese men after 4 weeks of PIO treatment,
although changes at 2 weeks of treatment were not assessed
(unpublished data).
Apart from the changes in plasma adiponectin induced by PIO
treatment in these men without diabetes, there were no changes
in fasting levels of plasma glucose, insulin, or FFA, indicating the
utility of a dynamic testing platform, like the hyperinsulinemic
clamp, in assessing changes in IR. Furthermore, the feasibility of
employing individuals without diabetes was demonstrated,
thereby obviating a confounding potential effect of reversing
glucotoxicity. It is worth noting that the baseline insulin sensitivity
of the study participants, which was conﬁrmed by baseline clamp
determinations, was efﬁciently and accurately predicted using
standard clinical parameters, as outlined in the Methods section.
Finally, the ﬁndings in placebo-treated study participants, who
also underwent 3 separate clamp measurements across an approx-
imately 4-week interval (and in the absence of diet or activity
interventions) ﬁlls a void in the literature concerning reproduci-
bility. Technical parameters upon which clamp measurements are
closely dependent, namely clamped levels of glucose and insulin,
were tightly matched across the 3 clamp studies in the placebo
group. The parameter of reproducibility (observed CCC, 0.70–0.77)
is quite good, and in view of the technical consistency we are
conﬁdent that the residual variance probably represents biological
ﬂuctuation in IR in these individuals even across this relatively
short interval of time.
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Our ﬁndings demonstrate for the ﬁrst time in a randomized,
double-blind, placebo-controlled trial in obese volunteers with
nondiabetic IR that clearly interpretable evidence of amelioration
of IR can be detected across adipose, hepatic, and skeletal muscle
tissues as early as after 2 weeks of treatment with an insulin
sensitizer. PIO provided a good benchmark for detecting thera-
peutically relevant improvements in IR and its efﬁcacy was evident
in the clamp studies at 2 weeks by improvements in stimulation of
glucose disposal and suppression of FFA, as well as increases in
circulating adiponectin, with further improvement in the suppres-
sion of endogenous glucose production at 4 weeks of treatment.
Taken together, these data suggest that tissue crosstalk associated
with detectable improvements in insulin sensitivity occurs early
during treatment, setting the stage for further work to tease out
the underlying molecular mechanisms and interactions. Further-
more, because these data were acquired in the setting of a
controlled trial design using an approved antihyperglycemic agent
as a probe and a simple yet reliable experimental design and
methodology, a paradigm such as the one presented here can be
readily applied in early clinical development. This may be a very
useful and highly informative antecedent to support investment in
advancing novel insulin sensitizers into further phases of
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